Glaxo CEO Rules Out Large Deals, Eyes Smaller Cos: Handelsblatt
2015-04-07 06:33:00.783 GMT
By Alessandro Speciale
(Bloomberg) -- GlaxoSmithKline interested in buying small
tech cos up to $200m, rules out billion-dollar purchases,
Handelsblatt reports, citing interview with CEO Andrew Witty.
* Says prices in current pharma deals unjustified
* Glaxo to grow “faster than the market, which according to
our calculations should grow 3%-4%” after Novartis deal
* No plans to sell OTC unit, can’t rule out split in future
* Decision on selling stake in AIDS-drug joint venture with
Pfizer to come in June
* Glaxo has “great hopes” for respiratory system drugs
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Alessandro Speciale in Frankfurt at +49-69-9204-1201 or
aspeciale@bloomberg.net
To contact the editor responsible for this story:
Fergal O’Brien at +44-20-3525-7152 or
fobrien@bloomberg.net
2015-04-07 06:33:00.783 GMT
By Alessandro Speciale
(Bloomberg) -- GlaxoSmithKline interested in buying small
tech cos up to $200m, rules out billion-dollar purchases,
Handelsblatt reports, citing interview with CEO Andrew Witty.
* Says prices in current pharma deals unjustified
* Glaxo to grow “faster than the market, which according to
our calculations should grow 3%-4%” after Novartis deal
* No plans to sell OTC unit, can’t rule out split in future
* Decision on selling stake in AIDS-drug joint venture with
Pfizer to come in June
* Glaxo has “great hopes” for respiratory system drugs
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Alessandro Speciale in Frankfurt at +49-69-9204-1201 or
aspeciale@bloomberg.net
To contact the editor responsible for this story:
Fergal O’Brien at +44-20-3525-7152 or
fobrien@bloomberg.net